PRODUCT PIPELINE
our focus
Problem & Opportunity
No FDA approved drugs
- Proven animal models for rapid screening
- Local delivery method improves outcomes with fewer off-target concerns
- Federal funding for initial studies
- Team of recognized experts across range of auditory maladies
Product Pipelines
Robust pipeline for science-based solutions to hearing disorders
We have developed animal model systems for pre-clinical trials of drug candidates and have advanced our leading drug candidate to a clinical Phase II trial with the US Army. NIH-supported research is now enabling us to move additional candidates through our discovery pipeline.
Three Indications
Tinnitus
Tinnitus is the number one disability claim for military personnel
Hearing Loss
Prevalence of hearing loss and tinnitus in military population are greater than in the general public
Meniere’s disease
Characterized by fluctuating hearing loss, often debilitating vertigo, and roaring tinnitus that occurs in an episodic fashion. It’s estimated that there are 600,000-750,000 cases of Ménière’s disease in the United States
Products
4
Patents Filed
7
Papers Published
9
SBIR/STTR Grants Received
Our Strategy
New Drug Development
Utilizing 505(b)(2) regulatory pathway to repurpose FDA-approved drugs as tinnitus therapies
GW-TT2
Recently received positive feedback from FDA in preIND meeting for product development strategy
Targeted Delivery
Utilizing Adeno-Associated Virus (AAV)-based tools to target cells in the auditory pathway (or auditory system) as a tinnitus therapy
GW-TT5
Promising pre-clinical animal studies demonstrate that we are able to manipulate the tinnitus symptoms with gene therapy